These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 35309990)
21. An in silico analysis of effective siRNAs against COVID-19 by targeting the leader sequence of SARS-CoV-2. Pandey AK; Verma S Adv Cell Gene Ther; 2021 Apr; 4(2):e107. PubMed ID: 33786418 [TBL] [Abstract][Full Text] [Related]
22. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents. Nandi S; Roy H; Gummadi A; Saxena AK Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893 [TBL] [Abstract][Full Text] [Related]
23. ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2. Tribolet L; Alexander MR; Brice AM; van Vuren PJ; Rootes CL; Mara K; McDonald M; Bruce KL; Gough TJ; Shi S; Cowled C; Bean AGD; Stewart CR J Virol; 2021 Jul; 95(15):e0032721. PubMed ID: 33963054 [TBL] [Abstract][Full Text] [Related]
24. An ncRNA transcriptomics-based approach to design siRNA molecules against SARS-CoV-2 double membrane vesicle formation and accessory genes. Nawaz R; Arif MA; Ahmad Z; Ahad A; Shahid M; Hassan Z; Husnain A; Aslam A; Raza MS; Mehmood U; Idrees M BMC Infect Dis; 2023 Dec; 23(1):872. PubMed ID: 38087193 [TBL] [Abstract][Full Text] [Related]
25. Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection. Ren W; Zhu Y; Lan J; Chen H; Wang Y; Shi H; Feng F; Chen DY; Close B; Zhao X; Wu J; Tian B; Yuan Z; Zhou D; Saeed M; Wang X; Zhang R; Ding Q J Virol; 2022 Jan; 96(1):e0149221. PubMed ID: 34668773 [TBL] [Abstract][Full Text] [Related]
26. Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. Holwerda M; V'kovski P; Wider M; Thiel V; Dijkman R Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33256227 [TBL] [Abstract][Full Text] [Related]
27. Structure of Nonstructural Protein 1 from SARS-CoV-2. Clark LK; Green TJ; Petit CM J Virol; 2021 Jan; 95(4):. PubMed ID: 33234675 [TBL] [Abstract][Full Text] [Related]
28. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Zheng BJ; Guan Y; Tang Q; Du C; Xie FY; He ML; Chan KW; Wong KL; Lader E; Woodle MC; Lu PY; Li B; Zhong N Antivir Ther; 2004 Jun; 9(3):365-74. PubMed ID: 15259899 [TBL] [Abstract][Full Text] [Related]
29. The Endonucleolytic RNA Cleavage Function of nsp1 of Middle East Respiratory Syndrome Coronavirus Promotes the Production of Infectious Virus Particles in Specific Human Cell Lines. Nakagawa K; Narayanan K; Wada M; Popov VL; Cajimat M; Baric RS; Makino S J Virol; 2018 Nov; 92(21):. PubMed ID: 30111568 [TBL] [Abstract][Full Text] [Related]
30. Prediction of putative potential siRNAs for inhibiting SARS-CoV-2 strains, including variants of concern and interest. Saba AA; Adiba M; Chakraborty S; Nabi AN Future Microbiol; 2022 Apr; 17():449-463. PubMed ID: 35285248 [No Abstract] [Full Text] [Related]
31. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
32. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. Kumar SU; Priya NM; Nithya SR; Kannan P; Jain N; Kumar DT; Magesh R; Younes S; Zayed H; Doss CGP 3 Biotech; 2021 Apr; 11(4):198. PubMed ID: 33816047 [TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2. Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T Cells; 2021 Jun; 10(6):. PubMed ID: 34201214 [TBL] [Abstract][Full Text] [Related]
34. Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Dhorne-Pollet S; Fitzpatrick C; Da Costa B; Bourgon C; Eléouët JF; Meunier N; Burzio VA; Delmas B; Barrey E Front Microbiol; 2022; 13():915202. PubMed ID: 36386681 [TBL] [Abstract][Full Text] [Related]
35. Potential therapeutic road for targeting the SARS-CoV-2 at throat. Kaya M; Abuaisha AM; Serakinci N; Ozturk S Bratisl Lek Listy; 2021; 122(3):206-211. PubMed ID: 33618530 [TBL] [Abstract][Full Text] [Related]
36. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993 [TBL] [Abstract][Full Text] [Related]
37. Ferristatin II Efficiently Inhibits SARS-CoV-2 Replication in Vero Cells. Sokolov A; Isakova-Sivak I; Grudinina N; Mezhenskaya D; Litasova E; Kostevich V; Stepanova E; Rak A; Sychev I; Kirik O; Rudenko L Viruses; 2022 Feb; 14(2):. PubMed ID: 35215911 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes. Baldassi D; Ambike S; Feuerherd M; Cheng CC; Peeler DJ; Feldmann DP; Porras-Gonzalez DL; Wei X; Keller LA; Kneidinger N; Stoleriu MG; Popp A; Burgstaller G; Pun SH; Michler T; Merkel OM J Control Release; 2022 May; 345():661-674. PubMed ID: 35364120 [TBL] [Abstract][Full Text] [Related]
39. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]